Interferon-Alpha for Diabetes Mellitus Type 1
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00024518|
Recruitment Status : Completed
First Posted : September 19, 2001
Last Update Posted : November 19, 2013
|Condition or disease||Intervention/treatment||Phase|
|Insulin-Dependent Diabetes Mellitus||Drug: 30,000 units hrINF-alpha Drug: 5,000 hrINF-alpha Other: Placebo||Phase 2|
Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of the insulin-producing pancreatic beta-cells. The onset of clinical symptoms represents the endpoint of a chronic progressive decline in beta-cell function when the number of functional beta-cells descends below the critical mass required for maintenance of euglycemia (, ). However, the pancreas still retains the ability to produce a substantial amount of insulin. The goal of secondary prevention in T1DM is to avert further destruction of the remaining beta-cells and therefore delay or stop entry into the final stages of the disease associated with end organ damage.
The rationale for this study is to interfere with the autoimmune beta-cell destruction early on in order to preserve as much residual endogenous insulin production as possible. We plan to administer oral interferon-alpha (IFN-a) on a daily basis, which has been shown to modify the clinical course of diabetes, to alter cytokine release, and reduce expression of T cell activation markers in an animal model () and a pilot project in humans (S. Brod, University of Texas, unpublished data). The one-year study is designed as a double blind randomized protocol using either 5,000 or 30,000 units of IFN-a versus placebo. Five centers will participate in this protocol (University of Texas Health Science Center in Houston; Dallas; Children's Hospital, St. Paul, MN; Kansas City and NIH, Bethesda, Maryland).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||57 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Ingested Interferon-Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Diabetes Mellitus|
|Study Start Date :||September 2001|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
Placebo Comparator: Placebo
placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
placebo was prepared as saline alone with 6mg human serum albumin (HSA).
Experimental: 5,000 Units hrIFN-alpha
hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
Drug: 5,000 hrINF-alpha
Other Name: Human Recombinant Interferon-alpha
Experimental: 30,000 hrIFN-alpha
30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
Drug: 30,000 units hrINF-alpha
Other Name: Human Recombinant Interferon-alpha
- C-Peptide Level [ Time Frame: Baseline - 3mth, 6mnth, 9mnth, 12mnth ]The Connecting Peptide, or C-peptide, is a short 31-amino-acid protein that connects insulin's A-chain to its B-chain in the proinsulin molecule.
- Serum glucose [ Time Frame: baseline - 3mths, 6mnths, 9mnths, 12mnths ]Serum glucose or blood sugar measurements determine how much sugar is in the blood.
- Hemoglobin A1C [ Time Frame: Baseline - 3mnths, 6mnths, 9mnths, 12mnths ]a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00024518
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|United States, Minnesota|
|Children's Hospital - St. Paul|
|St. Paul, Minnesota, United States|
|United States, Missouri|
|Children's Hospital - Kansas City|
|Kansas City, Missouri, United States|
|United States, Texas|
|University of Texas, Dallas|
|Dallas, Texas, United States, 75216|
|University of Texas, Houston|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Kristina I Rother, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|
|Principal Investigator:||Staley A Brod, MD||The University of Texas Health Science Center, Houston|